Selected data models

You must log in to select data models for download or further analysis.

12 Search results.
Relevance Rating New first Old first

Visit 4 Dose 2 Diary Card - General Symptoms Biologicals HepA/HepB vaccine 208127/125

- 10/15/17 - 1 form, 8 itemgroups, 35 items, 1 language
Itemgroups: Header, Temperature, Headache, Malaise, Fatigue, Nausea, Vomiting, Other General Symptoms
Visit 4 Dose 2 Diary Card - General Symptoms form Study ID: 208127/125 Clinical Study ID: 208127/125 (Ext-HAB-038 Month 90) Study Title: A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Visit 6 Booster Dose Diary Card - General Symptoms Biologicals HepA/HepB vaccine 208127/125

- 10/15/17 - 1 form, 8 itemgroups, 35 items, 1 language
Itemgroups: Header, Temperature, Headache, Malaise, Fatigue, Nausea, Vomiting, Other General Symptoms
Visit 6 Booster Dose Diary Card - General Symptoms form Study ID: 208127/125 Clinical Study ID: 208127/125 (Ext-HAB-038 Month 90) Study Title: A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Visit 6 Booster Dose Diary Card - General Symptoms Biologicals HepA/HepB vaccine 208127/125

- 10/15/17 - 1 form, 8 itemgroups, 35 items, 1 language
Itemgroups: Header, Temperature, Headache, Malaise, Fatigue, Nausea, Vomiting, Other General Symptoms
Visit 6 Booster Dose Diary Card - General Symptoms form Study ID: 208127/125 Clinical Study ID: 208127/125 (Ext-HAB-038 Month 90) Study Title: A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Visit 3 Dose 1 Diary Card - General Symptoms Biologicals HepA/HepB vaccine 208127/125

- 8/29/17 - 1 form, 8 itemgroups, 35 items, 1 language
Itemgroups: Header, Temperature, Headache, Malaise, Fatigue, Nausea, Vomiting, Other General Symptoms
Visit 3 Dose 1 Diary Card - General Symptoms form Study ID: 208127/125 Clinical Study ID: 208127/125 (Ext-HAB-038 Month 90) Study Title: A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Eligibility Colorectal Neoplasms NCT00603577

- 1/6/18 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens; ODM derived from: https://clinicaltrials.gov/show/NCT00603577

Eligibility Chronic Hepatitis C Infection NCT00682591

- 12/3/17 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00682591

Eligibility Chemotherapeutic Agent Toxicity NCT00884767

- 7/12/17 - 1 form, 1 itemgroup, 22 items, 1 language
Itemgroup: Criteria
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin; ODM derived from: https://clinicaltrials.gov/show/NCT00884767

Eligibility Metastases NCT00305188

- 5/3/17 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.; ODM derived from: https://clinicaltrials.gov/show/NCT00305188

Eligibility Hepatitis C, Chronic NCT00227149

- 3/31/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT00227149

Visit 6 Booster Dose General Symptoms Biologicals HepA/HepB vaccine 208127/125

- 8/25/17 - 1 form, 11 itemgroups, 63 items, 1 language
Itemgroups: Header, SOLICITED ADVERSE EXPERIENCES - GENERAL SYMPTOMS, Temperature, Headache, Malaise, Fatigue, Nausea, Vomiting, Seriousness of symptoms, V. OTHER GENERAL SYMPTOMS, Administrative Data
Visit 6 Booster Dose General Symptoms form Study ID: 208127/125 Clinical Study ID: 208127/125 (Ext-HAB-038 Month 90) Study Title: A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Visit 4 Dose 2 General Symptoms Biologicals HepA/HepB vaccine 208127/125

- 8/24/17 - 1 form, 11 itemgroups, 63 items, 1 language
Itemgroups: Header, SOLICITED ADVERSE EXPERIENCES - GENERAL SYMPTOMS, Temperature, Headache, Malaise, Fatigue, Nausea, Vomiting, Seriousness of symptoms, V. OTHER GENERAL SYMPTOMS, Administrative Data
Visit 4 Dose 2 General Symptoms form Study ID: 208127/125 Clinical Study ID: 208127/125 (Ext-HAB-038 Month 90) Study Title: A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Visit 3 Dose 1 General Symptoms Biologicals HepA/HepB vaccine 208127/125

- 8/24/17 - 1 form, 11 itemgroups, 63 items, 1 language
Itemgroups: Header, SOLICITED ADVERSE EXPERIENCES - GENERAL SYMPTOMS, Temperature, Headache, Malaise, Fatigue, Nausea, Vomiting, Seriousness of symptoms, V. OTHER GENERAL SYMPTOMS, Administrative Data
Visit 3 Dose 1 General Symptoms form Study ID: 208127/125 Clinical Study ID: 208127/125 (Ext-HAB-038 Month 90) Study Title: A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial